Project Grant R01CA301042
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $716K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97213, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded University of California, San Diego a $699,929 Project Grant on June 20, 2025, under the Cancer Treatment Research program (CFDA 93.395) to enhance immunotherapy response in human papillomavirus negative head and neck squamous cell carcinoma (HPV-HNSCC). The project, which extends through May 31, 2030, focuses on improving dendritic cell (DC) migration to draining sentinel lymph nodes to enhance the efficacy of programmed...
- Federal Grant Award Summary The University of Arkansas for Medical Sciences (UAMS) received a $628,980 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2031. The award supports research exploring the GSK3B-53BP1 axis in immune control of head and neck squamous cell carcinoma (HNSCC), with the objective of enhancing T cell survival and anti-tumor immune responses. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Oregon Health & Science University $2,265,578 through the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to support a four-year research project concluding August 31, 2029. The funded research investigates androgen receptor (AR) signaling in conventional dendritic cells (CDCs) and its relationship to sex-based differences in anti-tumor immune function, with particular focus on melanoma....
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $521,002 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), with an award date of March 26, 2026, and completion date of February 28, 2031. The grant funds development and validation of a bone metastasis-on-a-chip microphysiological platform designed to advance understanding of prostate cancer metastasis to bone, which occurs in over 80% of...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary Oregon Health & Science University received a $625,179 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 26, 2026, with an ultimate completion date of February 28, 2031. The award funds research to develop and validate MCL1 (myeloid cell leukemia-1) inhibitor therapies, alone and in combination with existing chemotherapy, to treat lung metastasis in osteosarcoma patients. The research addresses a...
- Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The University of Southern California received a $712,735 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, with a completion date of April 30, 2030. This award supports a Phase II randomized clinical trial investigating the synergistic therapeutic potential of SEPHB4-HSA, an ephrinB2 inhibitor, combined with pembrolizumab (PD-1 antibody) in muscle invasive bladder cancer (MIBC) patients....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...